Evaxion A/S (EVAX) News
Follow Evaxion A/S (EVAX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Evax reports EPS of $(0.01), beating $(0.31) estimate
Evax reported EPS of $(0.01) versus an Est. of $(0.31), a 96.77% beat, and EPS was up 50% YoY from $(0.02).
EARNINGS | Aug 20, 2026, 11:33 AM UTC
L
Evaxion reports Q2 basic EPS of -$0.01
Evaxion reports Q2 basic EPS of -$0.01, with net income of -$3.729 million, pretax profit of -$3.933 million and operating income of -$3.846 million.
EARNINGS | Aug 20, 2026, 11:30 AM UTC
L
Evaxion issues business update and Q2 2026 financial results
Evaxion (EVAX) announces a business update alongside its second quarter 2026 financial results.
EARNINGS | Aug 20, 2026, 11:30 AM UTC
L
Evaxion expands R&D pipeline with AI-designed EVX-05 vaccine program
Evaxion says it expands and refocuses its R&D pipeline with EVX-05, described as an AI-designed off-the-shelf brain cancer vaccine program.
EQUITY | Aug 17, 2026, 12:00 PM UTC
L
Evaxion to announce second-quarter 2026 results on August 20
Evaxion plans to announce a business update and second-quarter 2026 financial results on August 20, 2026.
EARNINGS | Aug 14, 2026, 12:00 PM UTC
L
Evaxion To Present New Preclinical Data For Vaccine Candidate EVX-V1 In Poster Session At IHW 2026
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidate Poster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal,
EQUITY | Jul 01, 2026, 12:01 PM UTC